Facebook
Twitter
LinkedIn
ForwardTitle
Category
Credits
Event date
Cost
- Sleep
- Diagnostic Tools
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
Drs Rosenberg and Krystal identify key steps in the diagnosis and treatment of insomnia disorder.
- Bipolar Disorder
- Depression
- Antidepressants
- Antipsychotics
- Child and Adolescent Psychiatry
- Diagnostic Tools
- Mood Disorders
- Patient/Physician Communication
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
Drs Findling and Goldberg offer expertise on the diagnosis and treatment of bipolar disorder in patients of all ages.
- Anticonvulsants
- Epilepsy
- Neurology
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
Drs Detyniecki and Penovich identify the need for emergency seizure response plans and the new rescue treatment options that may easily be used by patients with epilepsy and their caregivers.
- Renal Disease
- Adherence
- Cardiology
- Comorbidity
- Diagnostic Tools
- Education
- Medical Conditions
- Primary Care
- Side Effects
- Weight
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
Regular screening of UACR and adding finerenone to SGLT2 inhibitors can greatly impact T2D at risk for CKD. Join faculty as they discuss three patient cases.
- Myasthenia Gravis
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
Symptoms and disease pathophysiology of myasthenia gravis (MG) vary considerably with each patient, and their individual preferences and priorities add to the need for individualized treatment of this autoimmune disease. Research in MG has grown substantially in recent years. New treatments have the potential of being both effective and well tolerated, addressing the trade-off of choosing either efficacy or tolerability when selecting treatments. Promising investigational treatments that may become available in the future may allow more patients than ever before to achieve an asymptomatic state, with the ultimate goal being to turn off abnormal antibody production.
- Bipolar Disorder
- Bipolar Depression
- Depression
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
Bipolar disorder presents on a spectrum, with bipolar depression on one end and bipolar I on the other and a host of other presentations in between. As guidelines are updated and new treatments become available, developing individualized treatment regimens is key and collaboration between clinician and patient and family is critical in optimizing patient outcomes. Clinicians should use measurement-based care to assess whether treatment changes are necessary, which requires engaging with the patient to monitor efficacy and manage side effects.
- Schizophrenia/ Schizoaffective Disorders
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
$0.00
Schizophrenia affects 1% of the world’s population largely during a patient’s most productive years. Multiple treatments are available, however many gaps to recovery exist. Learn from experts diagnostic criteria for and defining recovery in schizophrenia.
- Schizophrenia/ Schizoaffective Disorders
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
$0.00
Negative symptoms contribute to poor functional outcomes in schizophrenia. Evaluating different symptom domains and understanding the disorder’s reward circuitry can help with intervention and patients’ leading more fulfilling lives.
- Schizophrenia/ Schizoaffective Disorders
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
$0.00
Side effects from medication have the greatest impact on adherence for patients with Schizophrenia. They lower quality of life, daily functioning, and satisfaction.
- Schizophrenia/ Schizoaffective Disorders
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
$0.00
Balancing symptoms and side effects is difficult when treating patients with schizophrenia. New approaches to treatment and new therapies in the pipeline offer hope for this difficult-to-treat mental health disorder.